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2013-2014 Influenza Season 
Week 13 ending March 29, 2014 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 13 (March 23-29, 2014), influenza activity continued to decrease in most 
regions of the United States. 
o Viral Surveillance: Of 5,206 specimens tested and reported during week 13 by U.S. World 
Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories, 652 (12.5%) were positive for influenza. 
o Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and 
influenza (P&I) was below the epidemic threshold. 
o Influenza-associated Pediatric Deaths: Three influenza-associated pediatric deaths were 
reported. 
o Influenza-associated Hospitalizations: A season-cumulative rate of 31.7 laboratory-
confirmed influenza-associated hospitalizations per 100,000 population was reported. 
o Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness 
(ILI) was 1.6%, which is below the national baseline of 2.0%. Two of 10 regions reported ILI 
at or above region-specific baseline levels. New York City experienced high ILI activity; two 
states experienced moderate ILI activity; three states experienced low ILI activity; 45 states 
experienced minimal ILI activity, and the District of Columbia had insufficient data. 
o Geographic Spread of Influenza: The geographic spread of influenza in five states was 
reported as widespread; Guam and four states reported regional influenza activity; the 
District of Columbia and 17 states reported local influenza activity; Puerto Rico and 23 
states reported sporadic influenza activity; one state reported no influenza activity, and the 
U.S. Virgin Islands did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative since September 29, 2013 (Week 40) 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
2009 
H1N1 A (H3) 
A 
(Subtyping 
not 
performed) 
B  Pediatric Deaths 
Nation Normal 12.5% 10 of 54 27,360 1,659 14,225 3,297 82 
Region 1 Elevated 25.1% 5 of 6 1,623 351 405 118 3 
Region 2 Elevated 20.4% 2 of 4 1,794 177 1,077 562 3 
Region 3 Normal 21.9% 1 of 6 4,453 189 425 243 7 
Region 4 Normal 9.4% 0 of 8 2,026 34 4,836 1,004 18 
Region 5 Normal 11.2% 0 of 6 3,155 101 600 95 6 
Region 6 Normal 9.7% 0 of 5 3,162 212 4,186 754 28 
Region 7 Normal 3.9% 0 of 4 1,318 50 50 31 4 
Region 8 Normal 4.8% 1 of 6 4,612 110 1,288 131 2 
Region 9 Normal 4.6% 1 of 5 2,875 307 1,222 287 10 
Region 10 Normal 4.9% 0 of 4 2,342 128 136 72 1 
* http://www.hhs.gov/about/regionmap.html 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands. 
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U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories located in all 50 states, 
Puerto Rico, and Washington D.C. report to CDC the number of respiratory specimens tested for 
influenza and the number positive by influenza virus type and influenza A virus subtype. The results 
of tests performed during the current week are summarized in the table below. 
 
Region specific data is available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
 Week 13 
No. of specimens tested 5,206 
No. of positive specimens (%) 652 (12.5%) 
Positive specimens by type/subtype  
Influenza A 315 (48.3%) 
          2009 H1N1 68 (21.6%)  
          H3    90 (28.6%)
          Subtyping not performed 157 (49.8%)  
Influenza B 337 (51.7%) 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2013-14 Season 
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Antigenic Characterization*: CDC has antigenically characterized 2,110 influenza viruses 
[1,657 2009 H1N1 viruses, 269 influenza A (H3N2) viruses, and 184 influenza B viruses] collected 
by U.S. laboratories since October 1, 2013 by hemagglutination inhibition (HI). 
• 2009 H1N1 [1,657]: 1,656 (99.9%) of 1,657 2009 H1N1 viruses tested were characterized 
as A/California/7/2009-like, the influenza A (H1N1) component of the 2013-2014 Northern 
Hemisphere influenza vaccine. One (0.1%) virus showed reduced titers with antiserum 
produced against A/California/7/2009. 
 
• Influenza A (H3N2) [269]: 264 (98.1%) of the 269 influenza A (H3N2) viruses tested have 
been characterized as A/Texas/50/2012-like, the influenza A (H3N2) component of the 
2013-2014 Northern Hemisphere influenza vaccine. Five (1.9%) viruses showed reduced 
titers with antiserum produced against A/Texas/50/2012. 
 
• Influenza B [184]: 124 (67%) of the 184 influenza B viruses tested belong to 
B/Yamagata/16/88-lineage and the remaining 60 (33%) influenza B viruses tested belong to 
B/Victoria/02/87 lineage. 
 
• Yamagata Lineage [124]: 124 influenza B/Yamagata-lineage viruses were 
characterized as B/ Massachusetts/2/2012-like, which is included as an influenza B 
component of the 2013-2014 Northern Hemisphere trivalent and quadrivalent influenza 
vaccines. 
 
• Victoria Lineage [60]: 60 influenza B/Victoria-lineage viruses were characterized as 
B/Brisbane/60/2008-like, which is included as an influenza B component of the 2013-
2014 Northern Hemisphere quadrivalent influenza vaccine. 
 
*For more information see the section on antigenic characterization in the MMWR “Update: 
Influenza Activity — United States and Worldwide, May 19–September 28, 2013”. 
 
 
Composition of the 2014-2015 Influenza Vaccine:  The World Health Organization (WHO) has 
recommended vaccine viruses for the 2014-2015 Northern Hemisphere influenza vaccines, and the 
Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee 
(VRBPAC) has made recommendations for the composition of the 2014-2015 influenza vaccines to 
be used in the United States.  Both agencies recommend that trivalent vaccines contain an 
A/California/7/2009-like (2009 H1N1) virus, an A/Texas/50/2012-like (H3N2) virus, and a 
B/Massachusetts/2/2012-like (B/Yamagata lineage) virus.  It is recommended that quadrivalent 
vaccines containing an additional influenza B virus contain a B/Brisbane/60/2008-like (B/Victoria 
lineage) virus in addition to the viruses recommended for the trivalent vaccines. These 
recommendations were based on global influenza virus surveillance data related to epidemiology 
and antigenic characteristics, serological responses to 2013-2014 seasonal vaccines, and the 
availability of candidate strains and reagents. 
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Antiviral Resistance: Testing of 2009 H1N1, influenza A (H3N2), and influenza B virus isolates for 
resistance to neuraminidase inhibitors (oseltamivir and zanamivir) is performed at CDC using a 
functional assay. Additional 2009 H1N1 and influenza A (H3N2) clinical samples are tested for 
mutations of the virus known to confer oseltamivir resistance. The data summarized below combine 
the results of both testing methods. These samples are routinely obtained for surveillance purposes 
rather than for diagnostic testing of patients suspected to be infected with antiviral-resistant virus. 
 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 
influenza A (H1N1) and A (H3N2) viruses (the adamantanes are not effective against influenza B 
viruses). Therefore, data from adamantane resistance testing are not presented below. 
 
Neuraminidase Inhibitor Resistance Testing Results 
on Samples Collected Since October 1, 2013 
 
Oseltamivir Zanamivir 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Influenza A 
(H3N2) 341 0 (0.0) 341 0 (0.0) 
Influenza B 221 0 (0.0) 221 0 (0.0) 
2009 H1N1 4,714* 55 (1.2) 1,647 0 (0.0) 
*Includes specimens tested in national surveillance and additional specimens tested at public health 
laboratories in 19 states (AZ, CA, CO, DE, FL, GA, HI, ID, MA, ME, MD, MI, MN, NY, PA, TX, UT, WA, 
and WI) who share testing results with CDC. 
 
The majority of currently circulating influenza viruses are susceptible to the neuraminidase inhibitor 
antiviral medications, oseltamivir and zanamivir; however, rare sporadic cases of oseltamivir-
resistant 2009 H1N1 and A (H3N2) viruses have been detected worldwide. Antiviral treatment with 
oseltamivir or zanamivir is recommended as early as possible for patients with confirmed or 
suspected influenza who have severe, complicated, or progressive illness; who require 
hospitalization; or who are at greater risk for serious influenza-related complications. Additional 
information on recommendations for treatment and chemoprophylaxis of influenza virus infection 
with antiviral agents is available at http://www.cdc.gov/flu/antivirals/index.htm. 
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Pneumonia and Influenza (P&I) Mortality Surveillance: During week 13, 6.5% of all deaths 
reported through the 122 Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 7.3% for week 13. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending March 29, 2014 
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Influenza-Associated Pediatric Mortality: Three influenza-associated pediatric deaths were 
reported to CDC during week 13. Two deaths were associated with influenza A viruses for which no 
subtyping was performed and occurred during weeks 9 and 12 (weeks ending March 1 and March 
22, 2014).  One death was associated with an influenza B virus and occurred during week 13 (week 
ending March 29, 2014). 
 
A total of 82 influenza-associated pediatric deaths have been reported during the 2013-2014 
season from Chicago [1], New York City [2] and 29 states (AR [4]; AZ [1]; CA [8]; FL [4]; GA [1]; IA 
[1]; IL [1]; KS [2]; KY [1]; LA [5]; MA [2]; MD [1]; ME [1]; MI [2]; MS [1]; NC [5]; NE [1]; NJ [1]; NV [1]; 
OK [2]; OR [1]; PA [3]; SC [2]; TN [4]; TX [17]; UT [2]; VA [1]; WI [2]; and WV [2]). 
 
Additional data can be found at http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2010-11 season to present 
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Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network 
(FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related 
hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) 
and adults (since the 2005-2006 influenza season).   
   
The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP) states 
(CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and additional Influenza Hospitalization Surveillance 
Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance 
during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 
season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT during the 
2011-2012 season; IA, MI, OH, RI, and UT during the 2012-2013 season; and MI, OH, and UT 
during the 2013-2014 season.  
 
Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and 
describe characteristics of persons hospitalized with severe influenza illness. The rates provided 
are likely to be an underestimate as influenza-related hospitalizations can be missed, either 
because testing is not performed, or because cases may be attributed to other causes of 
pneumonia or other common influenza-related complications.  
 
Between October 1, 2013 and March 29, 2014, 8,587 laboratory-confirmed influenza-associated 
hospitalizations were reported. This is a rate of 31.7 per 100,000 population. The highest rate of 
hospitalization remains among adults aged ≥65 years, followed by the 50-64 years and 0-4 years 
age groups. People 18-64 years accounted for approximately 60% of reported hospitalized cases. 
Among all hospitalizations, 7,941 (92.6%) were associated with influenza A, 553 (6.4%) with 
influenza B, 38 (0.4%) with influenza A and B co-infection, and 55 (0.6%) had no virus type 
information. Among those with influenza A subtype information, 124 (3.2%) were H3 and 3,741 
(96.8%) were 2009 H1N1.  
 
Clinical findings are preliminary and based on approximately 53% of cases with complete medical 
chart abstraction. The most commonly reported underlying medical conditions among adults were 
obesity, metabolic disorders, cardiovascular disease, and chronic lung disease (excluding asthma). 
Approximately 12% of hospitalized adults had no identified underlying medical conditions. The most 
commonly reported underlying medical conditions in children were asthma, neurologic disorders, 
chronic lung disease (excluding asthma), and obesity.  Approximately 43% of hospitalized children 
had no identified underlying medical conditions. Among 630 hospitalized women of childbearing 
age (15-44 years), 143 (22.7%) were pregnant. 
 
Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html 
and http://gis.cdc.gov/grasp/fluview/FluHospChars.html. 
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Data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance for influenza 
related hospitalizations in children and adults in 13 US states. Incidence rates are calculated using the National Center for 
Health Statistics’ (NCHS) population estimates for the counties included in the surveillance catchment area. 
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Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular diseases include conditions 
such as coronary heart disease, cardiac valve disorders, congestive heart failure, and pulmonary hypertension, does not 
include isolated hypertension;  Chronic lung diseases include conditions such as chronic obstructive pulmonary disease, 
bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease;  Immune suppression includes 
conditions such as immunoglobulin deficiency, leukemia, lymphoma, HIV/AIDS, and individuals taking 
immunosuppressive medications;  Metabolic disorders include conditions such as diabetes mellitus, thyroid dysfunction, 
adrenal insufficiency, and liver disease;  Neurologic disorders include conditions such as seizure disorders, cerebral 
palsy, and cognitive dysfunction;  Neuromuscular disorders include conditions such as multiple sclerosis and muscular 
dystrophy;  Obesity was assigned if indicated in patient’s medical chart or if body mass index (BMI) >30 kg/m2;  
Pregnancy percentage calculated using number of female cases aged between 15 and 44 years of age as the 
denominator;  Renal diseases include conditions such as acute or chronic renal failure, nephrotic syndrome, 
glomerulonephritis, and impaired creatinine clearance;  No known condition indicates that the case did not have any 
known underlying medical condition indicated in medical chart at the time of hospitalization. 
Includes only cases for which data collection has been completed through the medical chart review stage. 
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Outpatient Illness Surveillance: Nationwide during week 13, 1.6% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI). This percentage is below the national baseline of 2.0%. (ILI is defined as 
fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.) 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, 2013-14 and Selected Previous Seasons 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.6% to 3.7% during 
week 13. Two of 10 regions reported a proportion of outpatient visits for ILI at or above their region-
specific baseline level. 
 
Region-specific data is available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
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Region 6 - AR, LA, NM, OK, TX
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Region 2 - NJ, NY, PR, USVI
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Region 3 - DE, DC, MD, PA, VA, WV
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Region 4 - AL, FL, GA, KY, MS, NC, SC, TN
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Region 5 - IL, IN, MI, MN, OH, WI
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Region 7 - IA, KS, MO, NE
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Region 8 - CO, MT, ND, SD, UT, WY
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Region 9 - AZ, CA, HI, NV
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ILINet Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during weeks with little or no 
influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity 
from outpatient clinics being below, or only slightly above, the average, to high, which would 
correspond to ILI activity from outpatient clinics being much higher than average. 
 
During week 13, the following ILI activity levels were experienced: 
 New York City experienced high ILI activity. 
 Two states experienced moderate ILI activity (New Jersey and Texas). 
 Three states experienced low ILI activity (Connecticut, Delaware, and New York). 
 Forty-five states experienced minimal ILI activity (Alabama, Alaska, Arizona, Arkansas, 
California, Colorado, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, 
Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North 
Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South 
Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and 
Wyoming). 
 Data were insufficient to calculate an ILI activity level for the District of Columbia. 
 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a 
state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city 
could cause the state to display high activity levels. 
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the 
full picture of influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports 
from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received. 
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of 
data completeness with data presented by the state likely being the more complete. 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the severity of influenza activity. 
 
During week 13, the following influenza activity was reported: 
 Widespread influenza activity was reported by five states (Connecticut, Delaware, 
Massachusetts, New Jersey, and New York). 
 Regional influenza activity was reported by Guam and four states (Maine, New Hampshire, 
Rhode Island, and Utah). 
 Local influenza activity was reported by the District of Columbia and 17 states (Arizona, 
Florida, Illinois, Iowa, Louisiana, Maryland, Michigan, New Mexico, North Carolina, Ohio, 
Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, and Virginia). 
 Sporadic influenza activity was reported by Puerto Rico and 23 states (Alabama, Alaska, 
Arkansas, California, Colorado, Georgia, Hawaii, Indiana, Kansas, Kentucky, Minnesota, 
Mississippi, Missouri, Montana, Nebraska, Nevada, North Dakota, South Dakota, Vermont, 
Washington, West Virginia, Wisconsin, and Wyoming). 
 One state reported no influenza activity (Idaho). 
 The U.S. Virgin Islands did not report.  
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/overview.htm 
Report prepared: April 4, 2014. 
          
 
Additional National and International Influenza Surveillance Information 
 
FluView Interactive: FluView includes enhanced web-based interactive applications 
that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These 
FluView Interactive applications allow people to create customized, visual interpretations of 
influenza data, as well as comparisons across flu seasons, regions, age groups and a variety of 
other demographics. To access these tools visit www.cdc.gov/flu/weekly/fluviewinteractive.htm.  
 
U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local 
influenza information. 
 
Alabama Alaska Arizona Arkansas California 
Colorado Connecticut Delaware District of Columbia Florida 
Georgia Hawaii Idaho Illinois Indiana 
Iowa Kansas Kentucky Louisiana Maine 
Maryland Massachusetts Michigan Minnesota Mississippi 
Missouri Montana Nebraska Nevada New Hampshire 
New Jersey New Mexico New York North Carolina North Dakota 
Ohio Oklahoma Oregon Pennsylvania Rhode Island 
South Carolina South Dakota Tennessee Texas Utah 
Vermont Virginia Washington West Virginia Wisconsin 
Wyoming New York City Virgin Islands 
 
Google Flu Trends: Google Flu Trends uses aggregated Google search data in a model created in 
collaboration with CDC to estimate influenza activity in the United States. For more information and 
activity estimates from the U.S. and worldwide, see http://www.google.org/flutrends/. 
 
World Health Organization: Additional influenza surveillance information from participating WHO 
member nations is available through FluNet and the Global Epidemiology Reports.  
 
WHO Collaborating Centers for Influenza located in Australia, China, Japan, and the United 
Kingdom.  
 
Europe: WHO/Europe at http://www.euroflu.org/index.php and the European Centre for Disease 
Prevention and Control at 
http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_survei
llance_overview.aspx. 
 
Public Health Agency of Canada: The most up-to-date influenza information from Canada is 
available at http://www.phac-aspc.gc.ca/fluwatch/. 
 
Health Protection Agency (United Kingdom): The most up-to-date influenza information from the 
United Kingdom is available at 
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/. 
 
 
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not 
constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and 
none should be inferred. CDC is not responsible for the content of the individual organization web pages found 
at these links.  
 
